SELP and acute chest syndrome: In contrast, crizanlizumab (SelG1) downregulates endothelial expression of P-selectin, thereby reducing inflammation-mediated cell adhesion, vaso-occlusive episodes, and acute chest syndrome episodes in patients with sickle cell disease [66].